Revised response based on immunostains: Chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, atypical chronic lymphocytic leukemia, CD5+ marginal zone lymphoma, other low-grade B-cell lymphoma. This evidence concerns the gene CD5 and B-cell non-Hodgkin lymphoma.